A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : PD-L1

Search Conditions:
Search Keyword : PD-L1
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: PD-L1
Appearance Frequency: 4485 time(s)
Long forms: 36

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
programmed death-ligand 1
(4104 times)
Neoplasms
(1809 times)
PD-1 (1008 times)
NSCLC (641 times)
OS (476 times)
2004 Schistosoma mansoni worms induce anergy of T cells via selective up-regulation of programmed death ligand 1 on macrophages.
PD-1 ligand
(278 times)
Neoplasms
(105 times)
PD-1 (192 times)
CTLA-4 (32 times)
NSCLC (31 times)
2001 Laser capture microdissection-based expression profiling identifies PD1-ligand as a target of the nude locus gene product.
protein ligand 1
(48 times)
Neoplasms
(18 times)
NSCLC (13 times)
ICIs (11 times)
CTLA-4 (7 times)
2016 Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody.
PD-1 and its ligand
(9 times)
Neoplasms
(3 times)
PD-1 (2 times)
Abs (1 time)
EBV (1 time)
2007 Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection.
anti-PD-ligand 1
(7 times)
Neoplasms
(3 times)
PD-1 (5 times)
CTLA-4 (3 times)
ACC (1 time)
2017 Biomarkers to predict prognosis and response to checkpoint inhibitors.
programmed death-1 receptor and its ligand
(4 times)
Neoplasms
(2 times)
CT (1 time)
CTLA-4 (1 time)
irAEs (1 time)
2014 Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-line.
programmed cell death 1
(3 times)
Medicine
(1 time)
HNSCC (2 times)
CTLA-4 (1 time)
eTregs (1 time)
2018 Mouse-Derived Gastric Organoid and Immune Cell Co-culture for the Study of the Tumor Microenvironment.
anti-PD-1 ligand
(2 times)
Neoplasms
(1 time)
PD-1 (2 times)
CLL (1 time)
DCs (1 time)
2020 Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy.
programmed death protein-ligand 1
(2 times)
Neoplasms
(2 times)
PD-1 (1 time)
smRCC (1 time)
VEGFR2 (1 time)
2020 New emerging targets in cancer immunotherapy: the role of VISTA.
10  programmed death-ligand 1 receptor
(2 times)
Neoplasms
(2 times)
OS (2 times)
AR (1 time)
BMI (1 time)
2019 Prognostic markers in salivary gland cancer and their impact on survival.
11  1-PD-1-ligand
(1 time)
Biological Therapy
(1 time)
APCs (1 time)
CTLA-4 (1 time)
PD (1 time)
2003 T cell costimulatory pathways: blockade for autoimmunity.
12  anti-anti-Programmed Death Ligand-1
(1 time)
Neoplasms
(1 time)
ICI (1 time)
mccRCC (1 time)
NSCLC (1 time)
2021 Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC).
13  demonstratedprogrammed death ligand-1
(1 time)
GI (1 time)
IHC (1 time)
NCCN (1 time)
2020 Gastric Cardia Adenocarcinoma with Metastasis to the Scalp: A Case Report.
14  PD-1 and its 2 B7 family ligands, B7-H1
(1 time)
Hematology
(1 time)
CTLs (1 time)
HA (1 time)
2007 Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells.
15  PD-1 engagement to its ligand
(1 time)
Molecular Biology
(1 time)
CMV (1 time)
PD-1 (1 time)
2006 Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction.
16  PD-1 ligand expression
(1 time)
Neoplasms
(1 time)
CTLA-4 (1 time)
PD-1 (1 time)
SITC (1 time)
2016 Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
17  PD-1 ligand-positive T cells
(1 time)
Allergy and Immunology
(1 time)
IFN (1 time)
IL (1 time)
MTB (1 time)
2016 Programmed death-1+ T cells inhibit effector T cells at the pathological site of miliary tuberculosis.
18  PD-1 on CD4+CD25+ Tregs, CD19+ cells and its ligand
(1 time)
Allergy and Immunology
(1 time)
BI (1 time)
2016 Increased IL-35 producing Tregs and CD19+IL-35+ cells are associated with disease progression in leprosy patients.
19  PD-1 on Tcells and its ligand
(1 time)
Biological Science Disciplines
(1 time)
APCs (1 time)
2018 Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells.
20  PD-1 on Tregs, B cell and its ligand
(1 time)
Allergy and Immunology
(1 time)
BI (1 time)
2016 Increased IL-35 producing Tregs and CD19+IL-35+ cells are associated with disease progression in leprosy patients.
21  PD-1 receptor ligand
(1 time)
Immune System Diseases
(1 time)
PD-1 (1 time)
2014 Autoimmunity as a double agent in tumor killing and cancer promotion.
22  PD-1, namely, B7-H1
(1 time)
Allergy and Immunology
(1 time)
DCs (1 time)
PD-1 (1 time)
2002 Expression of programmed death 1 ligands by murine T cells and APC.
23  PD-1, the ligand of which
(1 time)
Antineoplastic Agents
(1 time)
PD-1 (1 time)
2018 Improved outcomes with pembrolizumab treatment in two cases of double cancer including non-small-cell lung cancer.
24  PD-1-PD-ligand 1
(1 time)
Allergy and Immunology
(1 time)
IFN (1 time)
IL (1 time)
MTB (1 time)
2016 Programmed death-1+ T cells inhibit effector T cells at the pathological site of miliary tuberculosis.
25  PD-L1 and TGF-beta than patients with advanced invasive thymic carcinoma
(1 time)
OS (1 time)
PFS (1 time)
TETs (1 time)
2018 Impact of PD-L1, transforming growth factor-beta expression and tumor-infiltrating CD8+ T cells on clinical outcome of patients with advanced thymic epithelial tumors.
26  PD-L1 and, more recently, chromosomal 9p24.1/CD274
(1 time)
Pathology
(1 time)
FISH (1 time)
IHC (1 time)
PD-L2 (1 time)
2018 Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies.
27  PD-L1 IHC
(1 time)
Pathology
(1 time)
NSCLC (1 time)
2016 [Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].
28  PD-L1 protein expression using two IHC assays, mRNA
(1 time)
Neoplasms
(1 time)
NSCLC (1 time)
2019 PD-L1 gene copy number and promoter polymorphisms regulate PD-L1 expression in tumor cells of non-small cell lung cancer patients.
29  PD-L1 TM
(1 time)
Neoplasms
(1 time)
OS (1 time)
PD-L1 ME (1 time)
PFS (1 time)
2020 Prognostic significance of EGFR, MUC1 and PD-L1 expressions in cases with triple negative breast cancer.
30  PD-L1High
(1 time)
Neoplasms
(1 time)
ALDH (1 time)
PD-1 (1 time)
TNBCs (1 time)
2019 WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer.
31  plasma cells, are CD19-negative, and express B7-H1
(1 time)
Hematology
(1 time)
MM (1 time)
2009 A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients.
32  production of T cells via interaction with its ligands, B7-H1
(1 time)
Allergy and Immunology
(1 time)
--- 2013 Negative role of inducible PD-1 on survival of activated dendritic cells.
33  programmed cell death ligand 1 antibody
(1 time)
Physicochemical Phenomena
(1 time)
Treg (1 time)
2019 Regulatory T Cells Tailored with pH-Responsive Liposomes Shape an Immuno-Antitumor Milieu against Tumors.
34  programmed cell death receptor-1
(1 time)
Allergy and Immunology
(1 time)
DCs (1 time)
LPS (1 time)
MSCs (1 time)
2016 Mesenchymal Stem Cells Upregulate the Expression of PD-L1 But Not VDR in Dendritic Cells.
35  Programmed Death Cell Ligand 1
(1 time)
Pulmonary Medicine
(1 time)
OS (1 time)
TIMs (1 time)
2017 Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
36  programmed death-1 molecule ligand 1
(1 time)
Allergy and Immunology
(1 time)
CVID (1 time)
HLA-DR (1 time)
Ig (1 time)
2012 Monocyte activation is a feature of common variable immunodeficiency irrespective of plasma lipopolysaccharide levels.